Diagnostic Nuclear Medicines Market - Global Professional Analysis and Forecast to 2026

  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • The worldwide Diagnostic Nuclear Medicines market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 4.1% during the forecast period.

    This report presents the market size and development trends by detailing the Diagnostic Nuclear Medicines market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Diagnostic Nuclear Medicines market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Diagnostic Nuclear Medicines industry and will help you to build a panoramic view of the industrial development.

    Diagnostic Nuclear Medicines Market, By Type:

    • Tc-99m

    • F-18

    • Other

    Diagnostic Nuclear Medicines Market, By Application:

    • Oncology

    • Cardiology

    • Other

    Some of the leading players are as follows:

    • Bayer

    • Navidea

    • Novartis

    • Dongcheng

    • Lantheus

    • Triad Isotopes

    • Nordion

    • GE Healthcare

    • Jubilant Pharma

    • SIEMENS

    • Curium Pharmaceuticals

    • Eli Lilly

    • Bracco Imaging

    • China Isotope & Radiation

    Geographically, Major regions are analyzed in details are as follows:

    • North America

    • Europe

    • Asia Pacific

    • Latin America

    • Middle East & Africa

  • Table of Contents

    1 Methodology and Scope

    • 1.1 Market Segmentation & Scope

      • 1.1.1 Technology Type

      • 1.1.2 Product

      • 1.1.3 Application

      • 1.1.4 Regional scope

      • 1.1.5 Estimates and forecast timeline

    • 1.2 Research Methodology

    • 1.3 Information Procurement

      • 1.3.1 Purchased database

      • 1.3.2 Internal database

      • 1.3.3 Secondary sources

      • 1.3.4 Primary research

      • 1.3.5 Details of primary research

    • 1.4 Information or Data Analysis

      • 1.4.1 Data analysis models

    • 1.5 Market Formulation & Validation

    • 1.6 Model Details

      • 1.6.1 Commodity flow analysis

      • 1.6.2 Volume price analysis

    • 1.7 List of Secondary Sources

    • 1.8 List of Abbreviations

    2 Executive Summary

    • 2.1 Market Outlook

    • 2.2 Segment Outlook

    3 Market Variables, Trends, & Scope

    • 3.1 Market Lineage Outlook

    • 3.1.1 Parent market outlook

      • 3.1.2 Ancillary market outlook

    • 3.2 Market Segmentation

      • 3.2.1 Analysis

    • 3.3 Market Dynamics

      • 3.3.1 Market driver analysis

      • 3.3.2 Market restraint analysis

      • 3.3.3 Industry opportunities

    • 3.4 Penetration & Growth Prospect Mapping

      • 3.4.1 Penetration & growth prospect mapping analysis

    • 3.5 Business Environment Analysis Tools

      • 3.5.1 Porter's five forces analysis

      • 3.5.2 PESTLE analysis

      • 3.5.3 Major deals & strategic alliances analysis

    4 Diagnostic Nuclear Medicines Market: Technology Type Analysis

    • 4.1 Diagnostic Nuclear Medicines Technology Type Market Share Analysis, 2018 & 2026

    • 4.2 Diagnostic Nuclear Medicines Technology Type Market: Segment Dashboard

    • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

      • 4.3.1 Tc-99m

      • 4.3.2 F-18

      • 4.3.3 Other

    5 Diagnostic Nuclear Medicines Market: Product Analysis

    • 5.1 Diagnostic Nuclear Medicines Product Market Share Analysis, 2018 & 2026

    • 5.2 Diagnostic Nuclear Medicines Product Market: Segment Dashboard

    • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

    6 Diagnostic Nuclear Medicines Market: Application Analysis

    • 6.1 Diagnostic Nuclear Medicines Application Market Share Analysis, 2018 & 2026

    • 6.2 Diagnostic Nuclear Medicines Application Market: Segment Dashboard

    • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

      • 6.3.1 Oncology

      • 6.3.2 Cardiology

      • 6.3.3 Other

    7 Diagnostic Nuclear Medicines Market: Regional Analysis

    • 7.1 Diagnostic Nuclear Medicines Regional Market Share Analysis, 2018 & 2026

    • 7.2 Diagnostic Nuclear Medicines Regional Market: Segment Dashboard

    • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

    • 7.4 List of Players at Regional Level

      • 7.4.1 North America

      • 7.4.2 Europe

      • 7.4.3 Asia Pacific

    • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

      • 7.5.1 North America

      • 7.5.2 Europe

      • 7.5.3 Asia Pacific

      • 7.5.4 Latin America

      • 7.5.5 MEA

    • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

      • 7.6.1 North America

      • 7.6.2 Europe

      • 7.6.3 Asia Pacific

      • 7.6.4 Latin America

      • 7.6.5 Middle East & Africa

    8 Competitive Analysis

    • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

    • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

    • 8.3 Vendor Landscape

      • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

    9 Company Profiles

    • 9.1 Bayer

      • 9.1.1 Bayer Company overview

      • 9.1.2 Financial performance

      • 9.1.3 Product benchmarking

      • 9.1.4 Strategic initiatives

      • 9.1.5 SWOT analysis

    • 9.2 Navidea

      • 9.2.1 Navidea Company overview

      • 9.2.2 Financial performance

      • 9.2.3 Product benchmarking

      • 9.2.4 Strategic initiatives

      • 9.2.5 SWOT analysis

    • 9.3 Novartis

      • 9.3.1 Novartis Company overview

      • 9.3.2 Financial performance

      • 9.3.3 Product benchmarking

      • 9.3.4 Strategic initiatives

      • 9.3.5 SWOT analysis

    • 9.4 Dongcheng

      • 9.4.1 Dongcheng Company overview

      • 9.4.2 Financial performance

      • 9.4.3 Product benchmarking

      • 9.4.4 Strategic initiatives

      • 9.4.5 SWOT analysis

    • 9.5 Lantheus

      • 9.5.1 Lantheus Company overview

      • 9.5.2 Financial performance

      • 9.5.3 Product benchmarking

      • 9.5.4 Strategic initiatives

      • 9.5.5 SWOT analysis

    • 9.6 Triad Isotopes

      • 9.6.1 Triad Isotopes Company overview

      • 9.6.2 Financial performance

      • 9.6.3 Product benchmarking

      • 9.6.4 Strategic initiatives

      • 9.6.5 SWOT analysis

    • 9.7 Nordion

      • 9.7.1 Nordion Company overview

      • 9.7.2 Financial performance

      • 9.7.3 Product benchmarking

      • 9.7.4 Strategic initiatives

      • 9.7.5 SWOT analysis

    • 9.8 GE Healthcare

      • 9.8.1 GE Healthcare Company overview

      • 9.8.2 Financial performance

      • 9.8.3 Product benchmarking

      • 9.8.4 Strategic initiatives

      • 9.8.5 SWOT analysis

    • 9.9 Jubilant Pharma

      • 9.9.1 Jubilant Pharma Company overview

      • 9.9.2 Financial performance

      • 9.9.3 Product benchmarking

      • 9.9.4 Strategic initiatives

      • 9.9.5 SWOT analysis

    • 9.10 SIEMENS

      • 9.10.1 SIEMENS Company overview

      • 9.10.2 Financial performance

      • 9.10.3 Product benchmarking

      • 9.10.4 Strategic initiatives

      • 9.10.5 SWOT analysis

    • 9.11 Curium Pharmaceuticals

      • 9.11.1 Curium Pharmaceuticals Company overview

      • 9.11.2 Financial performance

      • 9.11.3 Product benchmarking

      • 9.11.4 Strategic initiatives

      • 9.11.5 SWOT analysis

    • 9.12 Eli Lilly

      • 9.12.1 Eli Lilly Company overview

      • 9.12.2 Financial performance

      • 9.12.3 Product benchmarking

      • 9.12.4 Strategic initiatives

      • 9.12.5 SWOT analysis

    • 9.13 Bracco Imaging

      • 9.13.1 Bracco Imaging Company overview

      • 9.13.2 Financial performance

      • 9.13.3 Product benchmarking

      • 9.13.4 Strategic initiatives

      • 9.13.5 SWOT analysis

    • 9.14 China Isotope & Radiation

      • 9.14.1 China Isotope & Radiation Company overview

      • 9.14.2 Financial performance

      • 9.14.3 Product benchmarking

      • 9.14.4 Strategic initiatives

      • 9.14.5 SWOT analysis

     

    The List of Tables and Figures (Totals 74 Figures and 135 Tables)

    • Figure Tc-99m Diagnostic Nuclear Medicines market, 2015 - 2026 (USD Million)

    • Figure F-18 Diagnostic Nuclear Medicines market, 2015 - 2026 (USD Million)

    • Figure Other Diagnostic Nuclear Medicines market, 2015 - 2026 (USD Million)

    • Figure Oncology market, 2015 - 2026 (USD Million)

    • Figure Cardiology market, 2015 - 2026 (USD Million)

    • Figure Other market, 2015 - 2026 (USD Million)

    • Table List of players in North America

    • Table List of players in Europe

    • Table List of players in Asia Pacific

    • Table SWOT analysis

    • Table North America Diagnostic Nuclear Medicines market, by country, 2015 - 2026 (USD Million)

    • Table North America Diagnostic Nuclear Medicines market, by type, 2015 - 2026 (USD Million)

    • Table North America Diagnostic Nuclear Medicines market, by product, 2015 - 2026 (USD Million)

    • Table North America Diagnostic Nuclear Medicines market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table U.S. Diagnostic Nuclear Medicines market, by type, 2015 - 2026 (USD Million)

    • Table U.S. Diagnostic Nuclear Medicines market, by product, 2015 - 2026 (USD Million)

    • Table U.S. Diagnostic Nuclear Medicines market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Canada Diagnostic Nuclear Medicines market, by type, 2015 - 2026 (USD Million)

    • Table Canada Diagnostic Nuclear Medicines market, by product, 2015 - 2026 (USD Million)

    • Table Canada Diagnostic Nuclear Medicines market, by application, 2015 - 2026 (USD Million)

    • Table Europe Diagnostic Nuclear Medicines market, by country, 2015 - 2026 (USD Million)

    • Table Europe Diagnostic Nuclear Medicines market, by type, 2015 - 2026 (USD Million)

    • Table Europe Diagnostic Nuclear Medicines market, by product, 2015 - 2026 (USD Million)

    • Table Europe Diagnostic Nuclear Medicines market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table U.K. Diagnostic Nuclear Medicines market, by type, 2015 - 2026 (USD Million)

    • Table U.K. Diagnostic Nuclear Medicines market, by product, 2015 - 2026 (USD Million)

    • Table U.K. Diagnostic Nuclear Medicines market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Germany Diagnostic Nuclear Medicines market, by type, 2015 - 2026 (USD Million)

    • Table Germany Diagnostic Nuclear Medicines market, by product, 2015 - 2026 (USD Million)

    • Table Germany Diagnostic Nuclear Medicines market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table France Diagnostic Nuclear Medicines market, by type, 2015 - 2026 (USD Million)

    • Table France Diagnostic Nuclear Medicines market, by product, 2015 - 2026 (USD Million)

    • Table France Diagnostic Nuclear Medicines market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Italy Diagnostic Nuclear Medicines market, by type, 2015 - 2026 (USD Million)

    • Table Italy Diagnostic Nuclear Medicines market, by product, 2015 - 2026 (USD Million)

    • Table Italy Diagnostic Nuclear Medicines market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Spain Diagnostic Nuclear Medicines market, by type, 2015 - 2026 (USD Million)

    • Table Spain Diagnostic Nuclear Medicines market, by product, 2015 - 2026 (USD Million)

    • Table Spain Diagnostic Nuclear Medicines market, by application, 2015 - 2026 (USD Million)

    • Table Asia Pacific Diagnostic Nuclear Medicines market, by country, 2015 - 2026 (USD Million)

    • Table Asia Pacific Diagnostic Nuclear Medicines market, by type, 2015 - 2026 (USD Million)

    • Table Asia Pacific Diagnostic Nuclear Medicines market, by product, 2015 - 2026 (USD Million)

    • Table Asia Pacific Diagnostic Nuclear Medicines market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table China Diagnostic Nuclear Medicines market, by type, 2015 - 2026 (USD Million)

    • Table China Diagnostic Nuclear Medicines market, by product, 2015 - 2026 (USD Million)

    • Table China Diagnostic Nuclear Medicines market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Japan Diagnostic Nuclear Medicines market, by type, 2015 - 2026 (USD Million)

    • Table Japan Diagnostic Nuclear Medicines market, by product, 2015 - 2026 (USD Million)

    • Table Japan Diagnostic Nuclear Medicines market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table India Diagnostic Nuclear Medicines market, by type, 2015 - 2026 (USD Million)

    • Table India Diagnostic Nuclear Medicines market, by product, 2015 - 2026 (USD Million)

    • Table India Diagnostic Nuclear Medicines market, by application, 2015 - 2026 (USD Million)

    • Table Latin America Diagnostic Nuclear Medicines market, by country, 2015 - 2026 (USD Million)

    • Table Latin America Diagnostic Nuclear Medicines market, by type, 2015 - 2026 (USD Million)

    • Table Latin America Diagnostic Nuclear Medicines market, by product, 2015 - 2026 (USD Million)

    • Table Latin America Diagnostic Nuclear Medicines market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Brazil Diagnostic Nuclear Medicines market, by type, 2015 - 2026 (USD Million)

    • Table Brazil Diagnostic Nuclear Medicines market, by product, 2015 - 2026 (USD Million)

    • Table Brazil Diagnostic Nuclear Medicines market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Mexico Diagnostic Nuclear Medicines market, by type, 2015 - 2026 (USD Million)

    • Table Mexico Diagnostic Nuclear Medicines market, by product, 2015 - 2026 (USD Million)

    • Table Mexico Diagnostic Nuclear Medicines market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Argentina Diagnostic Nuclear Medicines market, by type, 2015 - 2026 (USD Million)

    • Table Argentina Diagnostic Nuclear Medicines market, by product, 2015 - 2026 (USD Million)

    • Table Argentina Diagnostic Nuclear Medicines market, by application, 2015 - 2026 (USD Million)

    • Table MEA Diagnostic Nuclear Medicines market, by country, 2015 - 2026 (USD Million)

    • Table MEA Diagnostic Nuclear Medicines market, by type, 2015 - 2026 (USD Million)

    • Table MEA Diagnostic Nuclear Medicines market, by product, 2015 - 2026 (USD Million)

    • Table MEA Diagnostic Nuclear Medicines market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table South Africa Diagnostic Nuclear Medicines market, by type, 2015 - 2026 (USD Million)

    • Table South Africa Diagnostic Nuclear Medicines market, by product, 2015 - 2026 (USD Million)

    • Table South Africa Diagnostic Nuclear Medicines market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Nigeria Diagnostic Nuclear Medicines market, by type, 2015 - 2026 (USD Million)

    • Table Nigeria Diagnostic Nuclear Medicines market, by product, 2015 - 2026 (USD Million)

    • Table Nigeria Diagnostic Nuclear Medicines market, by application, 2015 - 2026 (USD Million)

    • Table Recent Developments & Impact Analysis, by Key Market Participants

    • Table Recent Developments & Impact Analysis, by Key Market Participants

    • Table Company market position analysis

    • Table Company Profiles

    • Table Bayer Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Navidea Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Novartis Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Dongcheng Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Lantheus Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Triad Isotopes Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Nordion Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table GE Healthcare Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Jubilant Pharma Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table SIEMENS Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Curium Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Eli Lilly Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table Bracco Imaging Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table China Isotope & Radiation Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.